October 5, 2016 / 3:07 PM / in a year

BRIEF-Tenax Therapeutics provides clinical update for lead candidate Levosimendan

Oct 5 (Reuters) - Tenax Therapeutics Inc

* Tenax therapeutics provides clinical update for lead candidate Levosimendan

* Imperial college presents data from leopards trial in septic shock at esicm annual congress showing treatment ARM did not meet primary endpoint

* Following top-line data, full results from study are expected to be during first half of 2017

* If data is positive, Tenax would anticipate submitting a new drug application to U.S. Food and drug administration during 2017

* DSMB recommends continuation of trial following final safety analysis from first 621 patients

* Has enrolled 833 patients in phase 3 levo-cts trial in cardiac surgery patients

* Tenax unlikely to pursue further development for indication with respect to leopards trial Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below